Transcatheter Aortic Valve Replacement was the largest of Edwards Lifesciences Corp’s 3 reported lines in fiscal 2025, at $4.49B — 74% of $6.07B.
| Product and Service | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transcatheter Aortic Valve Replacement | $3.52B | $4.11B | $4.49B | ||||||||||||||
| Transcatheter Heart Valve Therapy | — | — | — | ||||||||||||||
| Salesrevenuenet | — | — | — | ||||||||||||||
| Revenue, Net | — | — | — | ||||||||||||||
| Surgical Structural Heart | $829.70M | $981.30M | $1.03B | ||||||||||||||
| Surgical Heart Valve Therapy | — | — | — | ||||||||||||||
| Critical Care | — | — | — | ||||||||||||||
| Net Sales | — | — | — | ||||||||||||||
| Transcatheter Mitral & Tricuspid Therapies | $116.10M | $352.10M | $550.60M | ||||||||||||||
| Total | $4.46B | $5.44B | $6.07B |
In fiscal 2025, which ended December 31, 2025, the 3 revenue lines Edwards Lifesciences Corp reported in this breakdown added up to $6.07B. That was up 11.5% from $5.44B in fiscal 2024. Transcatheter Aortic Valve Replacement was the largest revenue line, at $4.49B or 74.0% of the total, followed by Surgical Structural Heart ($1.03B, 17.0%) and Transcatheter Mitral & Tricuspid Therapies ($550.60M, 9.1%). Together, the two largest revenue lines made up 90.9% of this total.
Compared with fiscal 2024, Transcatheter Mitral & Tricuspid Therapies grew the fastest, rising 56.4% to $550.60M. Every sizeable revenue line reported in both years grew. Over fiscal 2022 to 2025, revenue across these revenue lines went from $4.46B to $6.07B, a compound annual growth rate of 10.8%. Transcatheter Aortic Valve Replacement's share of the total fell from 78.8% to 74.0% over the same years.
The table also keeps 6 revenue lines that Edwards Lifesciences Corp no longer reports, so earlier years can still be read on their original basis; use "Show 6 discontinued" beneath the table to see them. This breakdown covers 17 fiscal years between 2008 and 2025, as reported in Edwards Lifesciences Corp's annual filings.
United States was the largest of Edwards Lifesciences Corp’s 4 reported lines in fiscal 2025, at $3.54B — 58% of $6.07B.
| Segment | FY 2012 | FY 2014 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.63B | $3.21B | $3.54B | ||||||||
| Europe | $1.04B | $1.32B | $1.52B | ||||||||
| Rest Of World | $436.00M | $572.00M | $652.30M | ||||||||
| Japan | $359.50M | $339.80M | $354.70M | ||||||||
| Total | $4.46B | $5.44B | $6.07B |
In fiscal 2025, which ended December 31, 2025, the 4 segments Edwards Lifesciences Corp reported in this breakdown added up to $6.07B. That was up 11.5% from $5.44B in fiscal 2024. United States was the largest segment, at $3.54B or 58.4% of the total, followed by Europe ($1.52B, 25.0%) and Rest Of World ($652.30M, 10.8%). Together, the two largest segments made up 83.4% of this total.
Compared with fiscal 2024, Europe grew the fastest, rising 14.8% to $1.52B. Every sizeable segment reported in both years grew. Over fiscal 2022 to 2025, revenue across these segments went from $4.46B to $6.07B, a compound annual growth rate of 10.8%. United States held a steady share of about 58.4%.
This breakdown covers 11 fiscal years between 2012 and 2025, as reported in Edwards Lifesciences Corp's annual filings.
United States was the largest of Edwards Lifesciences Corp’s 4 reported lines in fiscal 2021, at $2.96B — 57% of $5.23B.
| Geography | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.06B | $2.53B | $2.52B | $2.96B | ||||||||||
| Salesrevenuenet | — | — | — | — | ||||||||||
| Revenue, Net | — | — | — | — | ||||||||||
| Europe | $885.10M | $941.20M | $973.60M | $1.19B | ||||||||||
| Net Sales | — | — | — | — | ||||||||||
| Japan | $396.80M | $444.70M | $460.10M | $528.90M | ||||||||||
| Rest Of World | $385.60M | $429.40M | $435.80M | $550.20M | ||||||||||
| Total | $3.72B | $4.35B | $4.39B | $5.23B |
In fiscal 2021, which ended December 31, 2021, the 4 regions Edwards Lifesciences Corp reported in this breakdown added up to $5.23B. That was up 19.3% from $4.39B in fiscal 2020. United States was the largest region, at $2.96B or 56.6% of the total, followed by Europe ($1.19B, 22.7%) and Rest Of World ($550.20M, 10.5%). Together, the two largest regions made up 79.4% of this total.
Compared with fiscal 2020, Rest Of World grew the fastest, rising 26.3% to $550.20M. Every sizeable region reported in both years grew. Over fiscal 2018 to 2021, revenue across these regions went from $3.72B to $5.23B, a compound annual growth rate of 12.0%. United States' share of the total rose from 55.2% to 56.6% over the same years.
The table also keeps 3 regions that Edwards Lifesciences Corp no longer reports, so earlier years can still be read on their original basis; use "Show 3 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2008 to 2021, as reported in Edwards Lifesciences Corp's annual filings.
Edwards Lifesciences Corp (EW) breaks its revenue down by revenue line, segment and region. In fiscal 2025, its largest revenue line was Transcatheter Aortic Valve Replacement, with $4.49B or 74.0% of the total, followed by Surgical Structural Heart at $1.03B (17.0%).
Transcatheter Aortic Valve Replacement was Edwards Lifesciences Corp's largest revenue line in fiscal 2025, with $4.49B in revenue, 74.0% of the $6.07B reported across its 3 revenue lines.
United States was Edwards Lifesciences Corp's largest segment in fiscal 2025, with $3.54B in revenue, 58.4% of the $6.07B reported across its 4 segments.
United States was Edwards Lifesciences Corp's largest region in fiscal 2021, with $2.96B in revenue, 56.6% of the $5.23B reported across its 4 regions.
Of the Edwards Lifesciences Corp revenue lines reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Transcatheter Mitral & Tricuspid Therapies grew the fastest, rising 56.4% from $352.10M to $550.60M.
Every figure is taken from Edwards Lifesciences Corp's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2008 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.